Literature DB >> 2155953

Silica-induced scleroderma.

U F Haustein1, V Ziegler, K Herrmann, J Mehlhorn, C Schmidt.   

Abstract

In a survey done in East Germany between 1981 and 1988, we found that 93 of 120 male scleroderma patients had long-term exposure to silica dust. We describe our findings in 12 patients with scleroderma and silicosis. The exposure time to silica dust was between 3 and 34 years; the interval between the beginning of exposure and the onset of scleroderma averaged 27.3 years (range 9 to 40 years). Antinuclear antibodies in titers between 80 and 10,240 with nucleolar and/or speckled patterns were found in 10 patients, antibodies against double-stranded DNA in three, Scl-70 (topoisomerase I) in three, and anticentromere antibodies in five. The following markers of collagen metabolism were increased in serum: beta-galactosidase in 12 patients, laminin peptide-P1 in 10 patients, N-terminal procollagen type III peptide in 10, and urinary sialic acid excretion in 7. We propose that crystalline particles of silica less than 5 microns may be phagocytosed by macrophages and release lymphokines and monokines, which activate fibroblasts and enhance their collagen and glycosaminoglycan synthesis. In addition, silica may act as an adjuvant to increase immune reactivity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155953     DOI: 10.1016/0190-9622(90)70062-m

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  24 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Lupus anticoagulant in silica-induced scleroderma.

Authors:  J M Durand; M F Aillaud; G Kaplanski; P Lefevre; M C Alessi; I Juhan-Vague; J Soubeyrand
Journal:  Clin Rheumatol       Date:  1992-09       Impact factor: 2.980

3.  Serum levels of soluble Fas ligand in patients with silicosis.

Authors:  A Tomokuni; T Otsuki; Y Isozaki; S Kita; H Ueki; M Kusaka; T Kishimoto; A Ueki
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 4.  Environmental risk factors of systemic sclerosis.

Authors:  Isabelle Marie; Jean-François Gehanno
Journal:  Semin Immunopathol       Date:  2015-07-04       Impact factor: 9.623

5.  Association of pulmonary silicosis and systemic sclerosis.

Authors:  Kaouther Ben Abdelghani; Alia Fazaa; Leila Souabni; Leith Zakraoui
Journal:  BMJ Case Rep       Date:  2015-01-27

6.  Macrophage silica nanoparticle response is phenotypically dependent.

Authors:  Heather L Herd; Kristopher T Bartlett; Joshua A Gustafson; Lawrence D McGill; Hamidreza Ghandehari
Journal:  Biomaterials       Date:  2015-03-23       Impact factor: 12.479

7.  A case of localized scleroderma in a sculptor and his wife.

Authors:  Richard Bakst; Carrie Kovarik; Victoria P Werth
Journal:  J Clin Rheumatol       Date:  2009-12       Impact factor: 3.517

8.  Antinuclear antibodies in patients with scleroderma (systemic sclerosis) and in their blood relatives and spouses.

Authors:  A J Barnett; L J McNeilage
Journal:  Ann Rheum Dis       Date:  1993-05       Impact factor: 19.103

9.  Autoantibodies in silicosis patients and in silica-exposed individuals.

Authors:  Gabriel Zaghi; Fábio Koga; Renato M Nisihara; Thelma L Skare; Antonieta Handar; Shirley R Rosa Utiyama; Marilia Barreto Silva
Journal:  Rheumatol Int       Date:  2009-08-25       Impact factor: 2.631

10.  Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours.

Authors:  A Tomokuni; T Aikoh; T Matsuki; Y Isozaki; T Otsuki; S Kita; H Ueki; M Kusaka; T Kishimoto; A Ueki
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.